Akt–RSK–S6 Kinase Signaling Networks Activated by Oncogenic Receptor Tyrosine Kinases

A. Moritz,Y. Li,A. Guo,J. Villén,Yi Wang,Joan Macneill,J. Kornhauser,K. Sprott,Jing Zhou,A. Possemato,J. Ren,P. Hornbeck,L. Cantley,S. Gygi,J. Rush

DOI: https://doi.org/10.1126/scisignal.2000998

IF: 9.517

2010-08-24

Science Signaling

Abstract:A phosphoproteomic analysis of signaling pathways downstream of oncogenic receptor tyrosine kinases identified potential therapeutic targets. Breaking a Deadly Addiction Most carcinomas are driven by aberrant signaling from receptor tyrosine kinases (RTKs) and, indeed, may become so dependent on these signals that they rely on them for survival. The enormous complexity of the downstream pathways, however, and the sheer numbers of potential targets, have made determining the substrates that mediate this “oncogene addiction” a daunting task. Moritz et al. developed a phosphoproteomic approach to identify targets of three core signaling pathways—all of which involve activation of AGC family kinases—downstream of oncogenic RTKs. They identified more than 300 phosphorylation targets of these signaling pathways, including a set of proteins downstream of three different oncogenic RTKs [c-Met, epidermal growth factor receptor (EGFR), and platelet-derived growth factor receptor α (PDGFRα)]. Moreover, they identified six targets of RTK signaling whose knockdown affected cell viability. A detailed analysis of one of these proteins—the chaperone SGTA—revealed a role for it in stabilization of PDGFRα and survival of cancer cells addicted to PDGFRα signaling. Receptor tyrosine kinases (RTKs) activate pathways mediated by serine-threonine kinases, such as the PI3K (phosphatidylinositol 3-kinase)–Akt pathway, the Ras–MAPK (mitogen-activated protein kinase)–RSK (ribosomal S6 kinase) pathway, and the mTOR (mammalian target of rapamycin)–p70 S6 pathway, that control important aspects of cell growth, proliferation, and survival. The Akt, RSK, and p70 S6 family of protein kinases transmits signals by phosphorylating substrates on an RxRxxS/T motif (R, arginine; S, serine; T, threonine; and x, any amino acid). We developed a large-scale proteomic approach to identify more than 300 substrates of this kinase family in cancer cell lines driven by the c-Met, epidermal growth factor receptor (EGFR), or platelet-derived growth factor receptor α (PDGFRα) RTKs. We identified a subset of proteins with RxRxxS/T sites for which phosphorylation was decreased by RTK inhibitors (RTKIs), as well as by inhibitors of the PI3K, mTOR, and MAPK pathways, and we determined the effects of small interfering RNA directed against these substrates on cell viability. Phosphorylation of the protein chaperone SGTA (small glutamine-rich tetratricopeptide repeat–containing protein α) at serine-305 was essential for PDGFRα stabilization and cell survival in PDGFRα-dependent cancer cells. Our approach provides a new view of RTK and Akt–RSK–S6 kinase signaling, revealing previously unidentified Akt–RSK–S6 kinase substrates that merit further consideration as targets for combination therapy with RTKIs.